Medical Technology

40 VCs and 5 funds investing in Medical Technology

VCs investing in Medical Technology

Golnaz Borghei

Principal

80%

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Golnaz Borghei invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

SeedSeries A

Olivia Doppler

ESG & Operations Associate

80%

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Olivia Doppler supports APEX Ventures, whose published strategy is: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

SeedSeries A

Anne Glover

Investment Committee Member, Amadeus APEX Technology Fund

80%

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Anne Glover invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

SeedSeries A

Hermann Hauser

Investment Committee Member, Amadeus APEX Technology Fund

80%

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Hermann Hauser invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

SeedSeries A

Tim Hos

Investment Associate

80%

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Tim Hos invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

SeedSeries A

Ion Hauer

Investment Partner

80%

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Ion Hauer invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

SeedSeries A

Bill Baumel

Managing Director

80%

Ohio Innovation Fund

Check: $500K-$4M, as published by Ohio Innovation Fund.

Bill Baumel invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.

Early Stage

Michael Hughes

Venture Partner

80%

Ohio Innovation Fund

Check: $500K-$4M, as published by Ohio Innovation Fund.

Michael Hughes invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.

Early Stage

Mike Triplett

Venture Partner

80%

Ohio Innovation Fund

Check: $500K-$4M, as published by Ohio Innovation Fund.

Mike Triplett invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.

Early Stage

Jeff Schumann

Venture Advisor

80%

Ohio Innovation Fund

Check: $500K-$4M, as published by Ohio Innovation Fund.

Jeff Schumann is listed in a Venture Advisor capacity at Ohio Innovation Fund. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Early Stage

Faith Voinovich

Principal

80%

Ohio Innovation Fund

Check: $500K-$4M, as published by Ohio Innovation Fund.

Faith Voinovich invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.

Early Stage

Dave Blivin

Managing Partner

80%

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Dave Blivin contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Pre-SeedSeedEarly Stage

Alain le Loux

General Partner

80%

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Alain le Loux contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Pre-SeedSeedEarly Stage

Lee Rand

Partner

80%

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Lee Rand contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Pre-SeedSeedEarly Stage

Ytsen van der Meer

Principal

80%

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Ytsen van der Meer contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Pre-SeedSeedEarly Stage

Sabine Jansen

Corporate & Investor Relations

80%

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Sabine Jansen contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Pre-SeedSeedEarly Stage

Shinjan Dasgupta

Technology Analyst

80%

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Shinjan Dasgupta contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Pre-SeedSeedEarly Stage

Daan Boekhoudt

Investment Analyst

80%

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Daan Boekhoudt contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Pre-SeedSeedEarly Stage

Charles Call

SLP & Venture Partner

80%

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Charles Call contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Pre-SeedSeedEarly Stage

Alan Abbott

SLP & Venture Partner

80%

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Alan Abbott contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Pre-SeedSeedEarly Stage

Marc Subirats

General Partner

80%

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Marc Subirats invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Pre-SeedSeedSeries A

Marta G. Zanchi

Founder and Managing Partner

80%

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Marta G. Zanchi invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Pre-SeedSeedSeries A

Jordi Pedrol

Head of Finance

80%

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Jordi Pedrol is listed in a Head of Finance capacity at Nina Capital. No person-specific investment authority is inferred; the firm's mandate is retained only as shared context.

Pre-SeedSeedSeries A

Sebastian Anastassiou

Partner

80%

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Sebastian Anastassiou invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Pre-SeedSeedSeries A

Yahel Halamish

Partner

80%

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Yahel Halamish invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Pre-SeedSeedSeries A

Kyle Sherrill

Investment Manager

80%

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Kyle Sherrill invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Pre-SeedSeedSeries A

Fiorela Kapllanaj

Senior Analyst

80%

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Fiorela Kapllanaj invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Pre-SeedSeedSeries A

Bob Schulz

Chief Partnership Officer

80%

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Bob Schulz is listed in a Chief Partnership Officer capacity at Nina Capital. No person-specific investment authority is inferred; the firm's mandate is retained only as shared context.

Pre-SeedSeedSeries A

Aline Noizet

Community Manager

80%

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Aline Noizet is listed in a Community Manager capacity at Nina Capital. No person-specific investment authority is inferred; the firm's mandate is retained only as shared context.

Pre-SeedSeedSeries A

Guillem Torruella

Visiting Analyst

80%

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Guillem Torruella invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Pre-SeedSeedSeries A

Olivia Escudero

Visiting Analyst

80%

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Olivia Escudero invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Pre-SeedSeedSeries A

Andreas Riegler

Founder & General Partner

80%

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Andreas Riegler invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

SeedSeries A

Wolfgang Neubert

General Partner

80%

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Wolfgang Neubert invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

SeedSeries A

Stefan Haubner

Founding Partner & General Partner

80%

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Stefan Haubner invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

SeedSeries A

Marcell Farkas

Chief Financial Officer

80%

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Marcell Farkas supports APEX Ventures, whose published strategy is: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

SeedSeries A

Hylton Kalvaria

Advisor

75%

Rock Health Capital

Check: Rock Health Capital does not publish a standard current check-size range on its official site.

Hylton Kalvaria is listed in a Advisor capacity at Rock Health Capital. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

SeedEarly Stage

Keith W. Anderson

Advisor

75%

Rock Health Capital

Check: Rock Health Capital does not publish a standard current check-size range on its official site.

Keith W. Anderson is listed in a Advisor capacity at Rock Health Capital. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

SeedEarly Stage

Monique Smith

Advisor

75%

Rock Health Capital

Check: Rock Health Capital does not publish a standard current check-size range on its official site.

Monique Smith is listed in a Advisor capacity at Rock Health Capital. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

SeedEarly Stage

Bill Evans

Founder and General Partner

75%

Rock Health Capital

Check: Rock Health Capital does not publish a standard current check-size range on its official site.

Bill Evans invests or supports investments through Rock Health Capital's published strategy: Invest in remarkable entrepreneurs working at the intersection of healthcare and technology to make healthcare massively better for every human being.

SeedEarly Stage

Sean Day

Principal

70%

Rock Health Capital

Check: Rock Health Capital does not publish a standard current check-size range on its official site.

Sean Day invests or supports investments through Rock Health Capital's published strategy: Invest in remarkable entrepreneurs working at the intersection of healthcare and technology to make healthcare massively better for every human being.

SeedEarly Stage

Funds focused on Medical Technology